
|Videos|June 14, 2018
AR-V7 Key in Tx of mCRPC
Author(s)Andrew Armstrong, MD
In this video, Dr. Andrew Armstrong explains why AR-V7–positive men rarely benefit from abiraterone or enzalutamide, and advises on AR-V7 testing as a clinical tool.
Advertisement
In this video, Dr. Andrew Armstrong explains why AR-V7–positive men rarely benefit from abiraterone or enzalutamide, and advises on AR-V7 testing as a clinical tool.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
2
How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?
3
FDA Approves Niraparib Regimen in BRCA2+ Metastatic CSPC
4
What is Cevostamab’s Mechanism of Action in Multiple Myeloma?
5
















































































